Company profile
Vir Biotechnology, Inc.
NASDAQ: VIR · Healthcare · Biotechnology
#393 of 1,417 Healthcare companies by revenue33rd-percentile growth
EA Score
48DFH 50DQ 56GM 19SS 65
v0.1 · 65/100 weight · provisional
↑ market scale, filing timeliness · ↓ 3-yr revenue growth, growth stability
Methodology →Revenue TTM
$65.5M
Rev growth YoY (TTM)
+214.0%
Net income (FY)
-$438.0M
Employees
367
as of 2026-08-09
Market cap
$1.5B
as of 2026-08-09
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$68.6M$68.6M2025
Net income-$438.0M-$438.0M2025
Operating income-$479.3M-$479.3M2025
Total assets$1.0B$1.0B2025
Liabilities$237.5M$237.5M2025
Equity$765.3M$765.3M2025
Revenue trend
FY2020 – FY2025 · USD
FY20
FY20
FY20
FY21
FY24
FY24
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
License And Collaboration Revenue92%
Other Revenue5%
Grant3%
By geography
Non-US97%
UNITED STATES3%
The read
What is Vir Biotechnology, Inc.’s revenue?
Vir Biotechnology, Inc. booked $68.6M in FY2025 revenue, contracting 7.6% year over year — slower than 67% of Healthcare companies we track, at a -638.9% net margin.
Peers · Healthcare
Black Diamond Therapeutics, Inc.60CPersonalis, Inc.59CRockwell Medical, Inc.60CIntellia Therapeutics, Inc.57CKura Oncology, Inc.39DPraxsyn Corporation——Neighbors
San Francisco →Key facts
CEOMarianne De Backer
SectorHealthcare
IndustryBiotechnology
HeadquartersSan Francisco, CA
ExchangeNASDAQ: VIR
Employees367
IPO date2019-10-11
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.